Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
GlobalData on MSN1d
NHS England to offer Daiichi Sankyo’s quizartinib for AMLThe UK Medicines and Healthcare products Regulatory Agency previously confirmed the asset’s safety and efficacy.
As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.
Analyst Robert Burns from H.C. Wainwright reiterated a Hold rating on Zymeworks (ZYME – Research Report) and keeping the price target at ...
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in ...
The firms will share data from the HERTHENA-Lung02 trial, in which patritumab deruxtecan improved patients' progression-free survival versus chemo.
At ESMO, Multiple Enhertu Studies Highlight Challenges of Selecting, Managing Breast Cancer Patients
Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback